Back to Trial

Oracle Runs

Oracle findings and outcome history for A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments (NCT06323928).

Runs
1
Findings
1
Latest Run
Apr 1, 2026, 6:36 PM
Resolution Evidence
Outcome
YES
Status
Resolved
Settlement Date
4/1/26 UTC
Executive Summary

Lundbeck publicly reported positive Phase IIb top-line results for PROCEED (NCT06323928), stating the IV part met the primary endpoint with a statistically significant reduction vs placebo in monthly migraine days. ClinicalTrials.gov confirms this is the exact Phase 2 trial in question.

Sources
Sponsormb.cision.com2/12/26
Lundbeck announces positive phase IIb top-line results with bocunebart (Lu AG09222; anti-PACAP mAb) in migraine prevention

Sponsor says the IV part of PROCEED (NCT06323928) met its primary endpoint, showing a statistically significant difference vs placebo in change from baseline in monthly migraine days over weeks 1-12.

View source
ClinicalTrialsclinicaltrials.gov2/2/26
Study Details | NCT06323928 | A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments

ClinicalTrials.gov identifies NCT06323928 as the Phase 2 PROCEED trial of Lu AG09222 vs placebo in migraine patients with unsuccessful prior preventive treatments.

View source
All Oracle Findings

Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.

YESAccepted98% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

Lundbeck publicly reported positive Phase IIb top-line results for PROCEED (NCT06323928), stating the IV part met the primary endpoint with a statistically significant reduction vs placebo in monthly migraine days. ClinicalTrials.gov confirms this is the exact Phase 2 trial in question.

Found Apr 1, 2026, 6:36 PMOutcome date Feb 12, 2026, 12:00 AMReviewed Apr 1, 2026, 6:36 PM
Sponsormb.cision.comFeb 12, 2026, 12:00 AM
Lundbeck announces positive phase IIb top-line results with bocunebart (Lu AG09222; anti-PACAP mAb) in migraine prevention
Sponsor says the IV part of PROCEED (NCT06323928) met its primary endpoint, showing a statistically significant difference vs placebo in change from baseline in monthly migraine days over weeks 1-12.
ClinicalTrialsclinicaltrials.govFeb 2, 2026, 12:00 AM
Study Details | NCT06323928 | A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments
ClinicalTrials.gov identifies NCT06323928 as the Phase 2 PROCEED trial of Lu AG09222 vs placebo in migraine patients with unsuccessful prior preventive treatments.
Outcome History

Public history of accepted oracle reviews and recorded outcome changes for this trial.

Accepted Oracle Review (Legacy)Apr 1, 2026, 6:36 PM

Will the results be positive?

PendingtoYEScurrentYES
GPT-5.4 (OpenAI)98% confidenceReviewed Apr 1, 2026, 6:36 PM

Lundbeck publicly reported positive Phase IIb top-line results for PROCEED (NCT06323928), stating the IV part met the primary endpoint with a statistically significant reduction vs placebo in monthly migraine days. ClinicalTrials.gov confirms this is the exact Phase 2 trial in question.